InSitu Biologics Launches Regulation A+ Investment Opportunity for Non-Opiate Painkiller AnestaGel™

WOODBURY, Minn., July 31, 2018 /PRNewswire/ -- InSitu Biologics, LLC (www.insitubiologics.com), an emerging drug company focused on development of a proprietary non-opioid pain treatment, AnestaGel™, has launched a $10 million stock offering using Regulation A+. Targeting the multi-billion dollar pain control market with AnestaGel, the pre-offering market capitalization for InSitu was just over $24 million. The Company had over $2 million in new equity reservations and nearly $1 million in preferred shares convert at the opening.

The Company has been qualified by the Securities and Exchange Commission (SEC) to offer common stock under Regulation A+ to all investors. To reserve shares or learn more about the offering please visit: Manhattan Street Capital, the premier Reg A+ crowd investing platform that is hosting and advising on the capital raise.

InSitu Biologic's lead product, AnestaGel, has been proven in pre-clinical studies as a long-lasting and fast-acting non-opiate painkiller, targeted for use in post-operative regional pain management. InSitu Biologics plans to use the Reg A+ financing to fund Phase 1 manufacturing, Phase 1 clinical study, and more pre-clinical studies of AnestaGel.

AnestaGel has completed numerous pre-clinical studies comparing intra-operative placement and site injections of AnestaGel and the industry leading non-opiate, sustained release, post-operative, pain treatment.  Those tests confirmed:

• AnestaGel consistently lasted up to 300% longer for pain treatment
• AnestaGel carried 8x more payload with no toxicity
• AnestaGel provided full nerve block beyond 72 hours

"We are pleased with the response from our current and potential investors in the Reg A+ offering," said CEO James Segermark. "I think that when people take the time to understand the preclinical work we have done and appreciate the beauty of our ability to tune the Matrix™ BioHydrogel – ultimately resulting in a family of AnestaGel products -- they will realize that we may have the revolutionary product that doctors have been seeking. If AnestaGel translates to people the way it has worked so far, we could help to disrupt the opioid epidemic."

[About InSitu Biologics]

InSitu Biologics, LLC, is a pre-clinical stage company that researches, develops, tests and manufactures implantable time release products composed of its proprietary tunable, bio-polymeric hydrogel, Matrix BioHydrogel. InSitu has developed AnestaGel, a patented drug, based on hydrogel technology originally created by scientists at the Cleveland Clinic. AnestaGel has unique features including complete biocompatibility, site specific placement, and tunable formulations. For more information visit https://www.manhattanstreetcapital.com/insitu-biologics-0

[Legal Disclaimer]

NO MONEY OR OTHER CONSIDERATION IS BEING SOLICITED AND, IF SENT IN RESPONSE, WILL NOT BE ACCEPTED. NO OFFER TO BUY THE SECURITIES CAN BE ACCEPTED AND NO PART OF THE PURCHASE PRICE CAN BE RECEIVED UNTIL THE OFFERING STATEMENT FILED BY THE COMPANY WITH THE SEC HAS BEEN QUALIFIED BY THE SEC. ANY SUCH OFFER MAY BE WITHDRAWN OR REVOKED, WITHOUT OBLIGATION OR COMMITMENT OF ANY KIND, AT ANY TIME BEFORE NOTICE OF ACCEPTANCE GIVEN AFTER THE DATE OF QUALIFICATION. AN INDICATION OF INTEREST INVOLVES NO OBLIGATION OR COMMITMENT OF ANY KIND.

Contact: James Segermark, 1-651-338-4801, [email protected] 

SOURCE InSitu Biologics, LLC